Stem cell-like protein expression in breast cancer cell lines by Sever, Nurettin İlter
 
 
                                                                       
  
                STEM CELL-LIKE PROTEIN EXPRESSION IN BREAST 
                                             CANCER CELL LINES                                               
 
 
 
                                     
                                         A THESIS SUBMITTED TO 
     THE DEPARTMENT OF MOLECULAR BIOLOGY AND GENETICS 
          AND THE INSTITUTE OF ENGINEERING AND SCIENCE OF 
                                             BİLKENT UNIVERSITY 
                IN PARTIAL FULFILLMENT OF THE REQUIREMENTS  
                      FOR THE DEGREE OF MASTER OF SCIENCE 
 
 
 
 
 
 
 
 
 
                                                               BY 
                                        NURETTİN İLTER SEVER 
                                                   AUGUST, 2003 
                                
 
 
                                                                                                                                                
                 
                                                          
                                                        
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                    
            
 
 
 
 
 
                                                       TO MY PARENTS, AND TO MY       
                                             GRANDMOTHER WHOM I LOST LAST               
                                                                       DECEMBER
                                                                                                                                                
 I certify that I have read this thesis and that in my opinion it is fully adequate, in     
scope and in quality, as a thesis for the degree of Master of Science. 
 
 
 
                                                                                                
                                                                                Prof. Dr. Mehmet Öztürk     
 
 
 
I certify that I have read this thesis and that in my opinion it is fully adequate, in 
scope and in quality, as a thesis for the degree of Master of Science. 
 
 
 
                                                                                                
                                                                                  Prof. Dr. Şevket Ruacan     
 
 
 
I certify that I have read this thesis and that in my opinion it is fully adequate, in 
scope and in quality, as a thesis for the degree of Master of Science. 
 
 
 
                                                                                                
                                                                                  Assist. Prof. Tamer Yağcı     
 
 
 
Approved for the Institute of Engineering and Science   
 
 
 
                                                                                                
                                                                                  Prof. Dr. Mehmet Baray  
                                             Director of Institute of Engineering and Science                                       
                                                                                                                                                                 i
   
  
                                                     
                                               ABSTRACT 
 
          Stem cell-like protein expression in breast cancer cell lines      
                                                 N.İlter Sever 
 
                        M.Sc. in Molecular Biology and Genetics 
                        Supervisor: Prof. Dr. Mehmet Öztürk 
                                             2003, 70 pages  
 
 
Breast cancer is the most common type of cancer and the second leading cause of 
cancer deaths among women. Most of breast carcinoma arises from the breast ductal 
epithelium. Recent studies in the past decade have displayed that many organs in our 
body possess organ-specific stem cells which have the capacity of self-renewal and 
differentiation toward specialized cell types which are specific for that organ. Breast 
is also one of these organs and breast epithelium contains stem/progenitor cells 
which give rise to two types of differentiated breast epithelial cell types: luminal 
epithelial and myoepithelial. Due to their property of division-competence for self-
renewal, stem cells are more prone to malignant transformation than more 
differentiated cell types. Therefore, it is considered that breast cancer may have 
arisen from a stem/progenitor cell found in mammary epithelium and recent studies 
support this hypothesis. In the study described in this thesis, breast cancer cell lines 
have been demonstrated to display stem/progenitor cell-like protein expression. 
Breast cancer cell lines have been characterized according to their marker protein 
expression related to the differentiation status of the mammary epithelial cell type by 
using immunofluorescence and Western blotting techniques. Also, single cell-
cloning of GI-101 cell line has been performed. It has been demonstrated that a 
single cell could give rise to different cell populations, further supporting the 
hypothesis that breast cancer cell lines display stem/progenitor cell-like protein 
expression. 
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                                                                             ÖZET 
 
     Meme kanseri hücre hatlarında kök hücre protein ekspresyonu  
                                                N.İlter Sever 
 
               Master Tezi, Moleküler Biyoloji ve Genetik Bölümü 
                      Tez yöneticisi : Prof. Dr. Mehmet Öztürk 
                                              2003, 70 sayfa 
 
Meme kanseri kadınlar arasında en yaygın ve en çok ölüme neden olan ikinci kanser 
türüdür. Meme kanserinin önemli bir kısmı meme kanal epiteli kökenlidir. Son on 
yıldaki çalışmalar vücudumuzdaki pekçok organın kendilerini yenileme ve o organa 
özel hücre tiplerine farklılaşabilme kapasiteleri olan kök/öncül hücrelere sahip 
olduklarını göstermiştir. Meme de bu organlardan biridir ve yapılan çalışmalar meme 
epitelinde farklılaşmış luminal epitel ve miyoepitel hücre tiplerine dönüşebilen 
kök/öncül hücrelerin varlığını ortaya koymuştur. Kendini yenilemek için bölünme 
potansiyelinin fazla olması kök/öncül hücreleri malignant dönüşüme farklılaşmış 
hücre tiplerine göre daha açık hale getirmektedir. Bu nedenle, meme kanserinin 
kök/öncül hücre kaynaklı olduğu düşünülmektedir ve yakın dönemdeki çalışmalar bu 
hipotezi desteklemektedir. Bu çalışmada, meme kanseri hücre hatlarında kök/öncül 
hücre protein ekspresyonu gösterilmiştir. Meme kanseri hücre hatları 
immünofloresan ve Western blotting metodları kullanılarak meme epiteli farklılaşma 
statüsünü belirleyici proteinlerin ekspresyonuna göre sınıflandırılmıştır. Ayrıca, GI-
101 hücre hattının tek hücre klonlaması yapılmış ve tek bir hücrenin birden fazla 
hücre tipine dönüşebildiği gösterilmiştir ve bu çalışma meme kanseri hücre 
hatlarında kök/öncül hücre protein ekspresyonunun var olduğu hipotezini 
desteklemektedir. 
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CHAPTER I         INTRODUCTION 
 
1.1  OVERVIEW OF HUMAN BREAST DEVELOPMENT: 
              
             Breasts are assumed to arise as the result of reciprocal epithelial and 
mesenchymal interactions. The mammary epithelium is an ectodermal derivative. 
Both male and female show the same pattern of development in utero. The prenatal 
breast development includes primarily condensation of epithelial cells in the 
thoracic/pectoral region where the breast bud forms. The nipple primordium forms 
as a narrow collection of epidermal cells. This nipple grows to a nodule which then 
gives rise to the formation of the breast bud. Mesenchymal cells condenses deeply 
around the breast bud and blood vessels form. The following event is branching of 
buds. Later, secondary buds appear, elongate and secondary buds branch and the 
breast bud invades into mesenchymal tissue and ductal morphogenesis occurs. At 
this stage, there is high expression of Epidermal Growth Factor Receptor (EGFR) 
and Transforming Growth Factor-alpha (TGF-α), suggesting an autocrine 
stimulation of proliferation (Howard and Gusterson, 2000; M.T.Lewis, 2000).  
 
             At the infant stage, both male and female show the same pattern of 
development. Wide variation is observed in the degree of glandular development and 
in the functional differentiation of the cells lining the ducts. At birth, the ductal 
system opens onto the surface through the breast pit, a small depression on the 
surface of the skin. The underlying mesenchyme proliferates to form a nipple. Whole-
mount analyses at birth demonstrate the diversity in the degree of development 
present, which can range from simple blunt-ended tubular structures to well-
developed branching. The infant breast is able to respond to the secretory stimuli that 
arise from maternal hormones and the production of milk by 80-90% of both sexes is 
due to the effects of prolactin on withdrawal of the sex steroids. Development of                       
                                                                                                                                                                 1
   
  
 interlobular and intralobular stroma containing fibroblast populations is observed at 
infant stage. During the first 2 years of life, the epithelium lining the ducts 
differentiates and involutes sequentially. The infant breast appears to undergo 
involution (death of epithelial cells by apoptosis) once it is removed from the 
influence of maternal hormones. By 2 years of age, only small ductal structures in a 
fibroblastic stroma are observed. The breast remains in this state until puberty 
(Howard and Gusterson, 2000).  
 
               At puberty, in females, ovarian hormones stimulate rapid and invasive 
ductal elongation driven by growth of a structure called the terminal end bud, which 
consists of four to six layers of relatively undifferentiated ‘body cells’ and a 
surrounding single layer of ‘cap cells’. Body cells differentiate into luminal 
epithelial cells, while cap cells differentiate into myoepithelial cells. Also, an 
increase in the amount of fatty and fibrous tissue (80%) is observed. The primary 
ducts branch leading to segmental and subsegmental ducts, which lead the terminal 
ducts that give rise to blind-ended ductules called acini. A collection of acini arising 
from one terminal duct and embedded in intralobular stroma is referred to as 
terminal duct lobular unit (TDLU), which is the functional unit of the breast. Upon 
reaching the limits of the fat pad at ductal maturity, ductal elongation ceases and 
terminal end buds regress to leave a branched system of differentiated ducts. These 
ducts will remain relatively quiescent as long as the animal remains virgin (Howard 
and Gusterson, 2000; M.T.Lewis, 2000).  
 
              Each pregnancy leads the breast to a cyclical growth pattern which contains 
lobuloalveolar differentiation, lactation, involution and gland remodeling processes. 
Hormonal changes during pregnancy lead to this  cyclical phase of development in 
which there is a dramatic transition from a predominantly ductal to a predominantly 
lobuloalveolar gland morphology. Lobuloalveolar progenitor cells located within the 
ducts proliferate to form alveolar buds, which further differentiate to form the 
alveoli. Near midpregnancy, the alveolar epithelium acquires the capacity to produce 
milk proteins (the stage I transition of lactogenesis) but secretory function is 
inhibited. At parturition, inhibition of secretory function is released and these cells 
begin to secrete large quantities of milk (the stage II transition of lactogenesis). 
Upon weaning, milk secretion ceases and the gland involutes. During involution, 
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 most alveolar cells undergo apoptosis (programmed cell death), while a residual 
epithelial population remodels itself back into a ductal tree to await the next 
pregnancy. During successive rounds of pregnancy and involution, the TDLUs 
expand and decrease in size with an increase and subsequent decrease in the number 
of acini (M.T.Lewis, 2000).  
                            
             At the postmenopousal involution stage, both lobules and ducts are reduced 
in number. The intralobular stroma is replaced by collagen, whereas the glandular 
epithelium and the interlobular connective tissue regress and are replaced by fat. 
The remainings are a few acini and ducts embedded in thin strands of collagen that 
are widely dispersed throughout the fat (Howard and Gusterson, 2000).  
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 1.2 BREAST CANCER 
 
1.2.1 EPIDEMIOLOGY OF BREAST CANCER 
 
1.2.1.1 Incidence of Breast Cancer 
             Breast cancer is the second leading cause of cancer deaths in women today 
(lung cancer is the first one) and is the most common cancer among women, 
excluding nonmelanoma skin cancers. According to the World Health Organization, 
more than 1.2 million people would be diagnosed with breast cancer in 2001 
worldwide (www.imaginis.com). The American Cancer Society estimates that in 
2001 approximately 192,200 new cases of invasive breast cancer would be diagnosed 
among women in the United States. Another 46,400 women would be diagnosed 
with ductal carcinoma in situ (DCIS), which will be introduced in part 1.2.2.2.2, a 
non-invasive breast cancer. DCIS is the earliest form of breast cancer, confined to the 
milk ducts of the breast. It is estimated that 40,600 deaths will occur from breast 
cancer (40,200 among women, 400 among men) in the United States 
(www.imaginis.com). Estimated breast cancer incidences and deaths are displayed in 
Table 1.1. The incidence rate of breast cancer (number of new breast cancers per 
100,000 women) increased by approximately 4% during the 1980s but leveled off to 
100.6 cases per 100,000 women in the 1990s. The death rates from breast cancer also 
declined significantly between 1992 and 1996, with the largest decreases among 
younger women. Medical experts attribute the decline in breast cancer deaths to 
earlier detection and more effective treatments (www.imaginis.com).  
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            Table 1.1 Estimated Breast Cancer Cases/Deaths Worldwide 
  
Region New Cases 
(2000) 
Deaths 
(2000) 
Eastern Africa 
Middle Africa 
Northern Africa 
Southern Africa 
Western Africa 
Caribbean 
Central America 
South America 
Northern America 
Eastern Asia 
South-Eastern Asia 
South Central Asia 
Western Asia 
Eastern Europe 
Northern Europe 
Southern Europe 
Western Europe 
Australia/New Zealand 
Melanesia 
Micronesia 
Polynesia 
13,615 
3,902 
18,724 
5,537 
17,389 
6,210 
18,663 
69,924 
202,044 
142,656 
55,907 
129,620 
20,155 
110,975 
54,551 
65,284 
115,308 
12,748 
470 
62 
127 
6,119 
1,775 
8,388 
2,504 
7,830 
2,310 
5,888 
22,735 
51,184 
38,826 
24,961 
62,212 
8,459 
43,058 
20,992 
25,205 
40,443 
3,427 
209 
28 
58 
                                                         
                                 
                                                             
 
 
         
t  ds              tt       
 
 
 
 
 
 
 
 
 
 
Source: J. Ferlay, F. Bray, P. Pisani and D.M. Parkin. GLOBOCAN 2000: Cancer 
Incidence, Mortality and Prevalence Worldwide, Version 1.0. IARC CancerBase No. 
5. Lyon, IARCPress, 2001 
               It has been estimated that approximately 50% of women who develop breast 
cancer have no identifiable risk factor beyond increasing age and female gender 
(Madigan et al., 1995). Age plays a major role in breast cancer risk (Ries et al., 
1999). In women under the age of 30, breast cancer is extremely uncommon.  
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 From 1992 to 1996, the incidence of breast cancer in women aged 35 to 39 was 59 
per 100.000 cases; however, in women aged 55 to 59, the incidence was 296 per 
100.000 cases. The annual incidence continues to rise, albeit more gradually, as a 
women enters her 60s and 70s (Ries et al., 1999). Breast cancer probability related 
with age of woman is displayed in Table 1.2. (www.imaginis.com) 
            
         Table 1.2 Breast Cancer Probability Related with Age of Woman 
 
   
           the tt 
tttttttlead to t              
T 
 
Source: Feuer EJ, Wun LM. DEVCAN: Probability of 
Developing or Dying of Cancer. Version 4.0. Bethesda MD: 
National Cancer Institute, 1999. 
   By age 30 
   By age 40 
   By age 50 
   By age 60 
   By age 70 
   By age 80 
   Ever 
  1 out of 2,212 
  1 out of 235 
  1 out of 54 
  1 out of 23 
  1 out of 14 
  1 out of 10 
  1 out of 8 
hther                                              
               Breast cancer in men is infrequent and in the year 2000, it was estimated 
that 1500 men would develop breast cancer and 400 of these men would die from 
the disease (Greenlee et al., 2000). The lifetime risk of being diagnosed with breast 
cancer in men is 0.11% compared with 13% in women (Brewster and Helzlouser, 
2001). The genetic syndrome, Klinefelter syndrome, which affects 1 in every 1000 
men, is responsible for 3 to 8% of male breast cancer cases (Hultborn et al., 1997). 
Other genetic causes of male breast cancer include inherited mutations in the breast 
cancer susceptibility genes BRCA1 and BRCA2 (Friedman et al., 1997; Couch et 
al., 1996). Nongenetic causes of male breast cancer include radiation exposure, liver 
disease, gynecomastia, obesity, and exposure to estrogen medication (Lynch et al., 
1999). 
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1.2.1.2 Risk Factors of Breast Cancer in Women 
             Multiple factors are associated with an increased risk of developing breast 
cancer, including increasing age, family history-inherited predisposition to breast 
cancer (BRCA1 and BRCA2), exposure to female reproductive hormones (both 
endogenous and exogenous), dietary factors, benign breast disease, and 
environmental factors (such as ionizing radiation). The majority of these factors 
convey a small to moderate increase in risk for any individual women (Dickson and 
Lippman, 2001). Attention will be concentrated on the endogenous hormonal effects 
on breast cancer since these effects relate to our study.  
 
1.2.1.2.1 Endogenous Hormonal Effects on Breast Cancer 
             The development of breast cancer in many women appears to be related to 
female reproductive hormones. Epidemiologic studies have consistently identified a 
number of breast cancer risk factors, each of which is associated with increased 
exposure to endogenous estrogens. Early age at menarche, nulliparity or late age at 
menopause increase the risk of developing breast cancer  (Gail et al., 1989; Rosner et 
al., 1996).  
             As described earlier, the age-specific incidence of breast cancer increases 
steeply with age, but the rate of this increase, in postmenopausal period, decreases to 
one-sixth of that of in premenopausal period. This decrease suggests that ovarian 
activity plays a major role in the etiology of breast cancer. The relative risk of 
developing breast cancer for a woman with natural menopause before age 45 is one-
half that of a woman whose menopause occurs after age 55 (Trichoupoulos et al., 
1972).           
             Age at menarche and the establishment of regular ovulatory cycles are 
strongly linked to breast cancer risk. Earlier age at menarche is associated with an 
increased risk of breast cancer (Kelsey et al., 1993); there appears to be a 20% 
decrease in breast cancer risk for each year that menarche is delayed (MacMahon et  
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 al., 1973). It must be noted that hormone levels through the reproductive years in 
women who experience early menarche may be higher than in women who undergo a 
later menarche (MacMahon et al., 1982). Additionally, late onset of menarche results 
in a delay in the establishment of regular ovulatory cycles, although there is some 
controversy over whether this delay confers any additional protective effect 
(MacMahon et al., 1982).  
             Age at first full-term pregnancy clearly influences breast cancer risk. Based 
on epidemiologic studies, women whose first full-term pregnancy occurs after age 30 
have a two- to fivefold increase in breast cancer in comparison with women who 
have a first full-term pregnancy before approximately age 18 (MacMahon et al., 
1970, Trichoupoulos et al., 1983). Nulliparous women are at greater risk for the 
development of breast cancer than parous women (MacMahon et al., 1970). During 
pregnancy, mammary cells differentiate into mature breast cells prepared for 
lactation. After this differentiation, these cells have a longer cell cycle, allowing 
more time for DNA repair in G1 (Russo et al., 1982). Breast cancer risk increases 
transiently after a pregnancy. The increased risk lasts approximately 10 years (Bruzzi 
et al., 1988). The reason for the increased risk has been hypothesized to be the 
increase in proliferation, growth, and maturation of breast cells preparing for 
lactation, leading to the development of mutations. Also, studies have suggested that 
a long duration of lactation reduces breast cancer risk in premenopausal women 
(Newcomb et al., 1994).    
 
1.2.2 MOLECULAR BIOLOGY OF BREAST CANCER 
1.2.2.1 Somatic Mutations in Breast Cancer 
             Breast cancer, like other forms of malignancy, is thought to progress by 
accumulation of a series of genetic and resulting phenotypic changes in the pathways 
regulating cellular proliferation, differentiation, death (apoptosis or necrosis), DNA 
repair, tissue compartmentalization, and responses to therapy (Dickson and Lippman, 
2001). Classical cytogenetic studies have revealed that genetic regions, which are 
frequently rearranged, amplified, deleted, or altered, have been commonly detected 
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 on chromosomes 1,3,6,7,8,9,11,13,15,16,17,18, and 20 (Schrock et al., 1996; Ried at 
al., 1995). 
             The most common genetic abnormality in the progression of sporadic breast 
cancer is the loss of heterozygosity (LOH). An LOH event uncovers the functional 
consequences of a mutation in an allele of a tumor suppressor gene by removal of the 
dominant, normal allele. For the sporadic breast cancer, LOH on chromosomes 17p, 
13q, 9p, and 16q lead to the inactivation of the tumor suppressor genes TP53 
(encoding p53 protein), RB-1 (encoding Rb protein), CDKN2 (encoding the p16 
protein), and CDH1 (encoding the E-cadherin protein), respectively. TP53, RB-1, and 
CDKN2 regulate the cell cycle, on the other hand CDH1 primarily regulates 
differentiation and tissue compartmentalization (Dickson and Lippman, 2001). 
Before LOH of the one allele, the other allele for these genes is inactivated by two 
different ways: Point mutation is more commonly observed for TP53 and Rb genes in 
contrast to CDKN2 and CDH1 genes, where gene methylation more commonly 
occurs (Brenner et al., 1995). 
             The second most common type of cytogenetic alteration in breast cancer 
appears to be gene amplification. Gene amplification involves the formation of extra-
chromosomal, self-replicating units and then the permanent incorporation of these 
genetic elements into chromosomal regions (Dickson and Lippman, 2001). The best-
established amplified and functional genes for mammary tumorigenesis detected to 
date are the growth factor receptor c-ERBB2 (encoding c-erbB-2 protein), the nuclear 
transcription factor c-MYC (encoding c-Myc protein), and the cell-cycle kinase 
regulator CCND1 (encoding cyclin D1 protein) (Ried at al., 1995; Knuulila et al., 
1998).  
             An important class of genes frequently altered in sporadic breast cancer is 
members of the epidermal growth factor receptor (EGFR) family of growth factor 
receptors. The members of this family of protooncogenes (EGFR, erbB-2 or Her-
2/neu, erbB-3, and erbB-4) all share extensive homology and encode transmembrane 
glycoproteins with tyrosine kinase activity. They become oncogenic through gene 
amplification or overexpression at the mRNA and protein levels, leading to 
aberrations in signal transduction pathways and deregulation of cellular proliferation 
(Bacus et al., 1994). All the members of this family have been described as 
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 overexpressed in breast carcinoma; the most extensively studied receptors, EGFR 
and c-erbB-2 are known to be overexpressed in 20 to 40 percent of breast cancers 
(Slamon et al., 1989; Lewis et al., 1990). Also, the growth factor TGF-α is a member 
of the EGF family and is a ligand for EGFR. Elevated expression of TGF-α has been 
consistently associated with neoplastic transformation, with transgenic mouse models 
providing direct evidence for the role of TGF-α in malignant transformation of breast 
epithelium (Sandgren et al., 1990). Another family, the fibroblast growth factors 
(FGFs) and their receptors are thought to play a role in breast cancer. In a study by 
Penault-Llorca et al. (1995), FGFR1 and FGFR4 were found to be expressed at high 
levels in the breast cancer cell lines and in the breast tumour samples studied. 
               Also, the anti-apoptotic protein bcl-2 was found to be overexpressed in 30 
to 45 percent of breast carcinoma cases (Joensuu et al., 1992). Bcl-2 expression in 
human breast tissue varies dramatically throughout the menstrual cycle, suggesting 
that bcl-2 regulation is hormone-dependent (Sabourin et al., 1994). 
               The E-cadherin protein is a calcium-dependent cell adhesion molecule, 
involved in homophilic cell-cell interactions, thus it is important for the maintenance 
of differentiation and tissue compartmentalization. Loss of function of E-cadherin 
seems to facilitate malignant invasive growth of breast cancer cells (Ingvarsson, 
1999). The E-cadherin gene, CDH1, has been found mutated in a large portion of 
lobular breast tumours (Berx et al., 1995; Vos et al., 1997). As described earlier, 
LOH is observed for E-cadherin gene. No mutations have been detected in the 
CDH1 gene in the ductal breast tumours. On the other hand, reduced expression of 
E-cadherin has been found in both lobular and ductal breast cancer (Oka et al., 
1993).     
               Cyclins are the molecules which are crucial for the maintenance of the cell 
cycle and which complex with cyclin-dependent kinases (cdks) to proceed the cell 
cycle. Upon formation of the complex, Cdks phosphorylate downstram targets to 
propel the cellular machinery into the next phase of the cell cycle (Marx et al., 1994). 
Overproduction of cyclins and cdks lead to the deregulation of the cell cycle and 
therefore uncontrolled cell division. In the study by Buckley et al. (1993), among 20 
breast cancer cell lines which were analyzed for the expression of cyclin A, B1, C, 
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 D1, D2, D3, and E, it was demonstrated that 7 of 20 cell lines displayed increased 
expression of cyclin D1. Five of the seven displayed increased overexpression of 
cyclin D, which is important for G1-S transition of the cell cycle. In the same study, 
45 percent of 124 primary breast tumors were displayed to have increased expression 
of Cyclin D1.    
Most of the somatic changes in breast cancer are summarized in Table 1.3 (Couch 
and Weber, 1997).    
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 Table 1.3 Somatic Changes in Breast Cancer 
Gene/Region   Modification   Frequency  
  EGFR  Overexpression          20-40 
  HER-2/neu  Overexpression          20-40 
  FGF-1/FGF-4  Overexpression          20-30 
  TGF-α  Overexpression           ND 
  Ha-ras  Mutation          5-10 
  c-src  Overexpression         50-70 
  TP53  Mutation/ 
 Inactivation 
   
        30-40 
 RB1   Inactivation         20 
 Cyclin D1  Overexpression        35-45 
 E-cadherin  Reduced/absent 
    expression 
 
       60-70 
 MMPs   Increased  
  expression 
 
       20-80 
 bcl-2  Overexpression        30-45 
 c-myc  Amplification        5-20 
 
cialhat give rise to blind-ended ductules called acini. 
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 1.2.2.2 Histology of Breast Cancer                                                    
                                
               The breast is composed of two main types of tissues: glandular tissues and 
stromal (supporting) tissues. Glandular tissue possesses the milk-producing lobules 
and the ducts (milk passages), while the stromal tissue contains the fatty and fibrous 
connective tissue (www.imaginis.com) 
                               
               Breast carcinoma arises from the epithelium of the mammary gland, which 
includes the milk-producing lobules and the ducts that carry milk to the nipple. 
Malignant transformation of the stromal, vascular, or fatty components of the breast 
is extremely rare. These facts may largely explain why breast size is not a risk factor 
for breast cancer, since all women have a similar amount of breast epithelium while 
breast size is determined largely by the amount of stromal and fatty tissue (Couch 
and Weber, 1997). 
               The breast tissue, during lifetime of a women, experiences some changes. 
These changes can include an increase in the number of breast cells (hyperplasia) or 
the emergence of atypical breast cells (atypical hyperplasia). In some instances, a 
portion of breast tissue that exhibits abnormal characteristics can eventually develop 
into a cancerous tumor. While the appearance of atypical hyperplasia increases the 
risk of breast cancer, not all women with abnormal breast cells go on to develop 
breast cancer.  
               The typical progression of breast cancer from a normal breast tissue is 
summarized below: 
Normal   →   Hyperplasia (increase in the number of cells)   →   Atypical 
hyperplasia  (increase in the number of abnormal cells, a marker for breast cancer)  
→   Carcinoma in situ  (cancer exists but it is limited to the ducts or lobules where it 
originally developed)   →   Invasive Cancer (cancer exists and has spread beyond the 
ducts or lobules where it originally developed) 
               Some breast tumours may skip one or more intermediate steps. In general, 
anything farther along than atypical hyperplasia is considered as a cancer. 
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              The benign, non-cancerous breast conditions include fibrocystic breast 
condition, cysts, galactoceles, fibroadenomas, phyllodes tumors, intraductal 
papillomas, granular cell tumors, duct ectasia, fat necrosis and breast inflammation-
mastitis (www.imaginis.com) 
 
1.2.2.2.1 Lobular Carcinoma in situ:  
               Literally meaning “in place,” the term “in situ” refers to a very early form 
of cancer.  In general, the term “in situ” is used to indicate that abnormal cancer cells 
are present but have not spread past the boundaries of glandular tissues where they 
initially developed.   Lobular carcinoma in situ (LCIS) refers to a sharp increase in 
the number, appearance, and abnormal behavior of cells contained in the milk-
producing lobules of the breast (found within the lobes) (www.imaginis.com) 
               LCIS is not a preinvasive lesion but appears to be a marker of increased risk 
for the development of invasive cancer. Clinical diagnosis of LCIS is not possible, 
since LCIS does not form a palpable lesion and therefore cannot be identified on 
physical examination and is not visible on mammography. Thus, the diagnosis of 
LCIS is made as an incidental finding on a breast biopsy obtained for diagnosis of an 
adjacent lesion. Evidence that LCIS is a marker lesion and not a true malignant 
lesion comes from studies demonstrating that the invasive cancer that may develop 
subsequently is likely to occur distant from the known focus of LCIS and is more 
often of ductal than lobular histology (Kinne et al., 1991). 
               The histologic features of LCIS show little variation and are usually easily 
recognized. LCIS is most often characterized by a solid proliferation of small cells, 
with small, uniform, round-to-oval nuclei, and variably distinct cell borders. LCIS is 
typically present in the terminal duct-lobular units and distends and distorts the 
involved spaces. In some instances, LCIS involve extralobular ducts. The growth 
within these ducts may be either solid or pagetoid (i.e., the LCIS cells are insinuated 
between the duct basement membrane and the native ductal epithelial cells (Winer et 
al., 2001). 
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              LCIS has a low proliferative rate, is typically positive for estrogen receptor 
(ER), and rarely shows overexpression of HER-2/neu, or accumulation of the p53 
protein (Albonico et al., 1998; Rudas et al., 1997; Bur et al., 1992). In addition, LCIS 
is characterized by loss of expression of the adhesion molecule E-cadherin (Vos et 
al., 1997).  
 
1.2.2.2.2 Ductal Carcinoma in situ: 
          Ductal carcinoma in situ refers to the most common type of noninvasive 
breast cancer in women. In DCIS, the cancer cells are limited to milk ducts in the 
breast and have not spread into the fatty breast tissue. 
               The term, ductal carcinoma in situ (DCIS), refers to a family of cancers that 
occur in the breast ducts.  There are two categories of DCIS: non-comedo and 
comedo.  The term, comedo, describes the appearance of the cancer.  When comedo 
type breast tumors are cut, the dead cells inside of them (necrosis) can be expressed 
out just like a comedo or blackhead on the skin. 
               The most common non-comedo types of DCIS are:  
• Solid DCIS: cancer cells completely fill the affected breast ducts.  
• Cribriform DCIS: cancer cells do not completely fill the affected breast ducts; 
there are gaps between the cells.  
• Papillary and micropapillary DCIS: the cancer cells arrange themselves in a 
fern-like pattern within the affected breast ducts; micropapillary DCIS cells 
are smaller than papillary DCIS cells.  
               Comedo type DCIS (also referred to as Comedocarcinoma) tends to be 
more aggressive than the non-comedo types of DCIS.  Pathologists are able to easily 
distinguish between comedo type DCIS and other non-comedo types when 
examining the cells under a microscope because comedo type DCIS tends to plug the 
center of the breast ducts with necrosis (dead cells).  When necrosis is associated 
with cancer, it often means that the cancer is able to grow quickly.  Necrosis is often 
seen with microcalcifications (tiny calcium deposits) (www.imaginis.com). 
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              A number of biological markers in DCIS lesions have been evaluated. These 
studies have generally shown that comedo-type DCIS lesions lack estrogen and 
progesterone receptors, overexpress the HER-2/neu (c-erbB-2) oncogene, show 
mutations of the p53 tumor suppressor gene with accumulation of its protein product 
(Albonico et al., 1998; Rudas et al., 1997) and demonstrate angiogenesis in the 
surrounding stroma (Guidi et al., 1994; Engels et al., 1997).   
 
1.2.2.2.3 Invasive Breast Cancer 
             Invasive breast cancer may be ductal or lobular in histologic type, and while 
there are a few distinguishing clinical features, the natural history and treatment of 
the two lesions are virtually identical. About 80 percent of invasive breast cancers 
are ductal carcinomas, in which carcinoma has first originated in the milk ducts of 
the breast and then spreads to the other parts of the body. Infiltrating lobular 
carcinoma, in which carcinoma has first originated in the lobules of the breast and 
then spreads to the other parts of the body, is less common, representing 5 to 10 
percent of the breast cancers (Couch and Weber, 1997). The remaining types of 
invasive breast cancer are very rare; some of these are tubular cancer, characterized 
by prominent tubule formation; medullary carcinoma, a lesion that appears poorly 
differentiated under the microscope but is thought to have a more favorable 
prognosis than other breast cancers (Fisher et al, 1990); mucinous (or colloid) 
carcinoma, characterized by the abundant accumulation of extracellular mucin, bulky 
tumors, and a good prognosis (Harris et al, 1992); and inflammatory breast cancer, in 
which the breast appears swollen and inflamed because cancer cells block the 
lymphatic vessels in the skin of the breast, preventing the normal flow of the lymph 
fluid and leading to reddened, swollen and infect-looking breast skin (Gunhan-Bilgen 
et al., 2002). 
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 1.3 STEM CELLS AND CANCER, POSSIBLE ROLE 
OF STEM CELLS IN BREAST CANCER  
 
1.3.1 STEM CELL CONCEPT 
                          
             Cell biologists refer to a stem cell in a tissue whose undifferentiated 
characteristics are conserved while it serves as a source of cells that undergo change, 
lose their division-competence and acquire specialized functions.  Therefore, a stem 
cell has two important properties to be determinant: 1) high capacity of self renewal,  
2) capability of differentiation into cells which have specialized functions. The 
potential of a stem cell differs depending on the tissue, the stage of morphogenesis 
(embryonic, pubertal, or post-pubertal) and the kind of population dynamics required 
to maintain tissue function. For instance, an embryonic stem cell is capable of 
producing the set of seed cells for embryonic body parts and whole organ systems, 
on the other hand, the potential of the stem cells of adult tissues is restricted to the 
production of the cell types for the tissue in which they reside, therefore, they are 
referred to as tissue-specific stem cells. Organs as diverse as liver (Michalopoulos et 
al., 1997), brain (McKay et al., 1997), intestine (Cosentino et al., 1996), skin (Jones 
et al., 1997), lung (Emura et al., 1997) and muscle (Ferrari et al., 1998) were 
described to contain organ-specific stem cells. More than one type of multipotent 
stem cell may be present in an organ system such as blood (Boll et al., 1980), 
intestine (Cosentino et al.,1996), cerebellum (Snyder et al., 1992), and retina (Turner 
et al., 1990). In all of the systems studied, it has been shown that the immediate 
progeny of a stem cell are division-competent. Therefore, there exists a hierarchy of 
division-competent cells. This consists of:  
 
1. stem cells, which can produce all the cell types of a tissue including new 
stem cells,  
2. progenitor cells, which are multipotent, but produce only a subset of the cell 
types of an organ  
3. lineage-limited or committed cells which produce one cell type before 
differentiating.  
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              Tissue-specific stem cells are capable of both symmetric and asymmetric 
mitosis. Symmetric mitosis yield two new stem cells when a stem cell divide, on the 
other hand, asymmetric mitosis yield two cells with alternate fates, one is a new 
stem cell and the other is a committed progenitor. This is the beginning of the 
generation of cell diversity. The capacity of asymmetric mitosis is not limited to 
primary stem cells as multilineage progenitors must also produce multiple cell types 
(Chepko and Smith, 1999).       
 
1.3.2 STEM CELLS AND CANCER 
               Since cancer is thought to be a clonal disease originating in changes in the 
regulation of cell replication, it seems likely that those cells in a tissue that are still 
capable of mitosis are the ones that sustain genetic changes that lead to 
tumorigenesis. Tissue-specific stem cells remain division-competent for the life of 
the individual. Because of their possible susceptibility to genetic mutations and the 
probability of their passing on such changes  to their progeny, tissue specific stem 
cells and their division-competent progeny are highly implicated in the processes of 
neoplasia. (Chepko and Smith, 1999).  
                                
                  For a stem cell to persist for a lifetime of an animal, self-renewal is a very 
crucial property. Since cancer can be considered to be a disease of unregulated self-
renewal, understanding the regulation of normal stem cell self-renewal is also 
fundamental to understanding the regulation of cancer cell proliferation. Due to the 
common property of self-renewal, newly arising cells can be assumed to appropriate 
the machinery for self-renewing cell division that is normally expressed in stem 
cells. It has been demonstrated that many pathways that are classically associated 
with cancer may also regulate normal stem cell development. Wnt (Zhu et al., 1999), 
Shh (Wechsler-Reya et al., 1999) and Notch (Varnum-Finney et al., 2000) pathways 
have been shown to contribute to the self-renewal of stem cells and/or progenitors in 
a variety of organs, including the hemapoietic and nervous systems. When 
dysregulated, these pathways can contribute to oncogenesis. Mutations of these 
pathways have been associated with a number of human tumours, including colon 
carcinoma (Polakis et al., 2000) and epidermal tumours (Chan et al., 1999) (Wnt), 
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 medulloblastoma (Wechsler-Reya et al., 2001) and basal cell carcinoma (Gailani et 
al., 1999) (Shh) and T-cell leukemias (Ellisen et al., 1991) (Notch). Stem cells are 
most probably the target of transformation in most types of cancers. Since stem cells 
have the machinery for self-renewal already activated, maintaining this activation 
may be simpler than turning it on de novo in a more differentiated cell.; that is; fewer 
mutations may be required to maintain self-renewal than to activate it ectopically. 
Also, unlike mature cells which die after short periods of time, stem cells often 
persist for long periods of time, leading to a much greater opportunity for mutations 
to accumulate in individual stem cells than in most mature cell types.  
 
               Many analogies can be considered between normal stem cells and 
tumorigenic cells, both have extensive proliferative potential and the ability to give 
rise to new (normal and abnormal) tissues. Both are composed of heterogenous 
combination of cells, with different phenotypic characteristics and different 
proliferative potentials. Since most tumours have a clonal origin, tumorigenic cancer 
cells must give rise to phenotypically diverse progeny, including cancer cells with 
indefinite proliferative potential, as well as cancer cells with limited or no 
proliferative potential. Although some of the heterogeneity in tumors arises as a 
result of continuing mutagenesis, it is likely that aberrant differentiation of cancer 
cells leads to this heterogeneity. In other words, both normal stem cells and 
tumorigenic cells give rise to phenotypically heterogenous cells that exhibit various 
degrees of differentiation. Thus, tumorigenic cells can be considered as cancer stem 
cells that undergo an aberrant and poorly regulated process of organogenesis 
analogous to what normal stem cells do.  
 
              There are two general models of heterogeneity currently discussed in solid 
cancer cells. One model proposes that cancer cells of many different phenotypes 
have the potential to proliferate extensively, but any one cell would have a low 
probability of exhibiting this potential in an assay of clonogenicity or tumorigenicity, 
while the other model proposes that although most cancer cells have only limited 
proliferative potential, only a subset of cancer cells consistently proliferate 
extensively in clonogenic assays and can form new tumours. Conventional therapies 
of cancer may shrink tumours by killing mainly cells with limited proliferative 
potential. If the putative cancer stem cells are less sensitive to these therapies, then 
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 they will remain viable after therapy and reestablish the tumour. On the other hand, 
if therapies can be targeted against cancer stem cells, then they might more 
effectively kill the cancer stem cells, rendering the tumours unable to maintain 
themselves or grow (Reya et al., 2001). 
 
 
1.3.3 MAMMARY EPITHELIAL STEM CELLS 
                            
             An important feature of the mammary gland is the regenerative capacity of 
its epithelium, demonstrated by successive reproductive cycles. During pregnancy in 
the mouse, a massive increase (25-27 fold) in the number of mammary epithelial 
cells occurs within the inguinal mammary fat pad (Kordon and Smith, 1998). As 
described earlier in part 1.1, this massive epithelial population is subsequently 
reduced following lactation through apoptotic cell death during involution. The 
subsequent events of cell growth and apoptotic cell death occur during and after each 
pregnancy period. This observation can be interpreted as an indication of the 
presence of a mammary epithelial stem cell (Chepko and Smith, 1999).   
                                 
               Serial passage of tissue fragments or dispersed cells transplanted to the 
proper tissue site in successive hosts is considered as the most stringent test for the 
existence of stem cells. The earliest serial transplantation experiments demonstrated 
that the self-renewal capability of the mammary epithelial cells persists for up to 
seven generations (Gardener and Hoshino, 1967). Daniel and Young (1971) serially 
transplanted epithelial ductal fragments into successive nulliparous hosts 
successfully until they had lost the ability to undergo branching morphogenesis, thus 
displayed the generative potency of mammary epithelial cells. The same researchers 
also displayed that when fragments from such senescent ducts were again 
transplanted into a host subsequently made pregnant, they were unable to produce 
branching ducts, however, developed secretory lobules along their length.. On the 
other hand, while carrying clonally-derived mammary outgrowths to senescence in 
breeding hosts, it was observed that certain fragments from randomly sampled 
outgrowths produced a complete ductal tree, but failed to produce secretory lobules. 
These experiments demonstrate that a mammary epithelial stem cell can produce at 
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 least two kinds of limited progenitors and the competence of production of these 
progenitors is controlled separately.  
                                
                It was shown that any fragment from lactating or involuted glands 
faithfully reproduces full lactating outgrowths in pregnant mice (Kordon and Smith, 
1998; Smith and Medina, 1988). Therefore, any part of the epithelium has the 
capacity to generate full complement of functional mammary epithelium. Whether 
one stem cell could produce an entire mammary gland was demonstrated by using 
mouse mammary tumor virus (MMTV) as an experimental model (Kordon and 
Smith, 1998). The researchers transplanted random fragments of MMTV-infected 
Czech mouse mammary epithelium. Since Czech mice have no endogenous nucleic 
acid sequences related to MMTV, nucleic acid homology with MMTV, 
demonstrated by using Southern blotting, in the epithelium of the MMTV-infected 
Czech mice from these outgrowths has pointed out the fact that an entire mammary 
gland may comprise the progeny of a single cell.  
                                
               Based on their observations under the electron microscope, two researchers 
(Chepko and Smith, 1999) could manage to characterize mammary cell morphotypes 
structurally and functionally. The researchers have taken “pale” or “light”-staining 
cells, which had been noticed before (Smith and Medina, 1988) in mouse mammary 
explants and which were the only cells that entered mitosis, as a beginning point of 
their studies. The basic properties of stem cells; division- competence, symmetric 
and asymmetric mitosis and a possible undifferentiated cytology were the guidelines 
for the researchers to characterize the mammary cell types. The presence of mitotic 
chromosomes referred to mitotic competence, while the appearance of side-by-side 
pairs of cells referred to symmetric cell division and the presence of one-above-the-
other pairs of cells referred to asymmetric cell division. The cytological 
differentiation of the cells were based on how many organelles they contain, how 
well developed the organelles are, whether they contain specialized proteins, and 
whether they demonstrate polarity (apical (facing the lumen) or basal (facing the 
stroma) orientation). Presence of milk protein granules, presence of Golgi vesicles 
and rough endoplasmic reticulum (RER), polar distribution of organelles, and 
luminal contact, which is a further indication of polarization, are prominent in the 
luminal cells of the mammary gland. On the other hand, myoepithelial cells are 
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 flattened, elongated cells located at the basal surface of the epithelium, and their 
cytoplasmic feature is the presence of an apically oriented nucleus and many basally 
distributed myofibrils (Smith and Chepko, 2001).  
                          
               The same researchers (Chepko and Smith, 1999) extended the classification 
of mammary cell morphotypes from two to five. The five morphotypes in mammary 
epithelium are: 
1. a morphologically primitive small light cell (SLC) 
2. a cytologically more complex, but still undifferentiated large light cell 
(ULLC) 
3. a cytologically very differentiated large light cell (DLLC) 
4. the classic cytologically complex luminal cell (large dark cell or LDC) 
5. the myoepithelial cell 
                            
               The structural and functional characteristics of mammary cell morphotypes 
(excluding myoepithelial cell) are displayed in Table 1.4 (Taken from Chepko and 
Smith, 1997). According to this classification, ultrastructurally, the putative stem 
cells reside in mammary epithelium basally (in contrast to apically) and also are 
distinct from the basally oriented myoepithelial cells.   
                
              These researchers then proposed a model of cell proliferation and 
differentiation in mammary epithelium based on morphological markers. According 
to this model, SLC (stem cells), devoid of differentiated characteristics, generate 
daughter cells morphologically similar to the mother cell. One of the daughters 
retains its undifferentiated nature and remains a stem cell. The sister cell, although 
remaining morphologically identical to the stem cell, becomes a primary progenitor 
cell with the capacity to undergo multiple divisions. All daughters of a primary 
progenitor cell divide, and, depending on the orientation of the cleavage furrow at 
the time of determination, differentiate into secondary progenitor cells (ULLC) that 
are committed either to secretory or to myoepithelial differentiation. ULLC can 
divide multiple times to produce large numbers of ULLC which differentiate into 
DLLC and then LDC. Alternatively, they can produce myoepithelial cells, but these 
are not produced in very large numbers. The model is summarized on Table 1.5 
(Taken from Chepko and Smith, 1997). 
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Table 1.4 Structural and Functional Characteristics of Mammary Cell Morphotypes  
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 Table 1.5 Cell Renewal in Mammary Epithelium 
 
               Normal human breast epithelium expresses an array of marker proteins that 
is indicative of the two lineages of the luminal and myoepithelial cells in the mature 
mammary gland. In the mature gland, the luminal epithelial cells express 
Cytokeratin 18 (CK18), Cytokeratin 19 (CK19), Epithelial Specific Antigen 
(ESA), and sialomucin (MUC1) (ESA is mostly expressed on the basal side of the 
luminal compartment on the other hand, MUC1 is expressed on the apical side of the 
luminal compartment), while the myoepithelial cells express Cytokeratin 14 
(CK14), vimentin, β4-integrin, common acute lymphoblastic leukemia antigen 
(CALLA), and α-smooth muscle actin (ASMA) (Jones et al., 1997; Petersen and 
van Deurs, 1988; Taylor-Papadimitrou et al., 1989). Also, the putative stem cells of 
the mammary gland are believed to express markers such as the basal cytokeratin 
Cytokeratin 5 (CK5) (Boecker et al., 2002) and Epithelial Specific Antigen (ESA) 
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 Balzar et al., 1999). Balzar et al. (1999) suggested that ESA is related to increased 
epithelial proliferation and negatively correlates with cell differentiation. Also, 
Gudjonsson et al. (2002) demonstrated that CK19 may be a potential marker for stem 
cell compartment of the mammary gland (described in detail below). These markers 
are used in the studies of mammary epithelial cells for the characterization of their 
differentiation status and constitute the basis of the study described in this thesis.  
               Two- or three-dimensional culture systems such as collagen or laminin in 
combination with flow cytometry and single cell sorting were used to demonstrate 
whether an epithelial cell population gives rise to any elaborate structure resembling 
in vivo such as terminal duct lobular unit (TDLU). Stingl et al. (1998) demonstrated 
that when cultured on Collagen gel as a basement membrane system, ESA-positive 
and MUC1-negative human breast epithelial cells (HBECs) give rise to mixed 
colonies of luminal and myoepithelial cells, therefore displaying stem/progenitor cell 
property. Dontu et al. (2003) has developed an in vitro cultivation system for 
propagation of human mammary stem/progenitor cells. In this study, mammary 
epithelial cells were cultivated as nonadherent mammospheres in suspension and the 
differentiation potential of these mammospheres were tested in reconstituted two-
dimensional culture systems such as Matrigel or collagen, it was demonstrated the 
nonadherent mammospheres have the capability of differentiation into luminal or 
myoepithelial cells. Gudjonsson et al. (2002) proposed that MUC1-negative/ESA-
positive cells exist in vivo. In the study, by using these cell surface markers and 
immunomagnetic sorting, MUC-negative/ESA-positive epithelial cell population was 
isolated and also immortalized by transduction of E6/E7 genes from human 
papilloma virus type 16 (HPV). In clonal cultures, this population gave rise to both 
differentiated ESA-positive/MUC1-positive luminal epithelial cells and 
differentiated ASMA-positive myoepithelial cells. Also, when cultured in laminin 
gel, this population formed branching structures resembling terminal duct lobular 
units (TDLU). Therefore, this population can be assumed as the stem/progenitor cell 
compartment of the breast.  This population was further characterized by the 
expression of Cytokeratin 19 (CK19) by immunofluorescence, therefore it was 
proposed that CK19 can be assumed as a marker for stem/progenitor cells, also 
CK19 was demonstrated not to be expressed in terminally differentiated ESA-
positive/MUC-positive luminal epithelial cells, in contrast to former studies (Bartek 
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 et al., 1985; Paine et al., 1992). In the study described in this thesis, CK19 was used 
as a marker for stem/progenitor cells.           
                The mammary epithelium developmental model described above by 
Chepko and Smith is further supported by the studies of Pechoux et al. (1999) and 
Stingl et al. (2001). Pechoux et al. (1999), devised two media specific for both 
luminal and myoepithelial cell lineages, respectively and grew the lineages in these 
media separately. When the media is switched to the other type, the luminal 
epithelial cells displayed conversion to myoepithelial cells, while the vice versa did 
not occur. This result suggests that human mammary luminal epithelial cells contain 
progenitors to myoepithelial cells. By using a combination of flow cytometry and in 
vitro colony assay procedures such as single cell culturing for human breast 
epithelial cells, Stingl et al. (2001) characterized bipotent mammary epithelial 
progenitor cells in normal adult human breast tissue when they observed colonies 
containing a central core of cells expressing luminal markers surrounded by CK14-
positive myoepithelial-like cells.   
 
1.3.4 MAMMARY EPITHELIAL STEM CELLS AND THEIR 
POSSIBLE ROLE IN BREAST CANCER      
               Colin R. Sharpe (1998) proposed a developmental hypothesis to explain the 
evolution of breast cancer.  According to her hypothesis, if a cell in a breast bud (the 
narrow collection of cells in the thoracic/pectoral region, described earlier in Part 
1.1) acquires a genetic mutation that is not repaired, the mutation is inherited to its 
progeny, thus carrying the mutation into multiple developing ductal systems. If a 
similar mutation occurs in a cell in the tip of one of the ducts, the daughter cells in 
that duct could inherit the genetic hit, but adjacent ducts might not, leading to 
“genetic mosaicism”. Therefore, earlier genetic mutations should result in larger 
altered areas.  
               The studies performed by Tsai et al. (1996) support this hypothesis. It has 
been shown that the mammary epithelium is a mosaic of discrete regions in which all 
cells have the same inactive X chromosome, suggesting that each region developed 
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 from the same stem cell. Entire lobules and large ducts had the same X chromosome 
inactivated. Therefore, it can be assumed that the lesions could have arisen within a 
population of mutated cells that arose from one stem cell, as the result of mutations 
that occurred after X-chromosome inactivation.  
               As described earlier in Part 1.2.1.2, the epidemiologic studies have 
indicated that breast cancer risk for a child-bearing women is linearly related to the 
age at which a women has her first full-term pregnancy and is higher in those who 
are nulliparous or late parous (MacMahon et al., 1970; Love et al., 1997; Canty, 
1997). This increased risk has been attributed to the stem cell multiplication that 
commences at the time of puberty and occurs during each ovarian cycle until the first 
pregnancy (Cairns et al., 1975) and to the induction of full differentiation of the 
mammary gland by pregnancy, which results in the refractoriness of the gland to 
carcinogenesis (Russo et al., 1990). Also, in the studies of the effects of radiation 
from the atomic bombs in Japan, the frequency of ionizing radiation-induced breast 
cancers has been inversely correlated with the age of the women at the time of 
exposure, indicating a higher breast cancer risk for the young undifferentiated 
mammary gland (Thompson et al., 1994). These studies are evidences about the role 
of the stem cell proliferation and differentiation in breast carcinogenesis.           
               Also, studies about loss of heterozygosity (LOH) in breast cancer further 
supported the role of stem cells in breast cancer. O’Connell et al. (1994) found that 
50% of benign proliferative breast lesions and 80% of DCIS lesions shared specific 
LOH patterns with more advanced lesions from the same breast, which pointed out 
an early LOH, most probably occurred in a stem cell, expanded by normal breast 
growth. In another study by Deng et al. (1996), DNA from breast cancer tissue was 
compared with DNA from adjacent, phenotypically normal terminal ductal-lobular 
units (TDLUs). In 8 of 30 cases LOH was found in both the cancerous tissue and the 
adjacent TDLUs, in which the same allele was missing in both types of tissue. Also, 
in the study by Lakhani et al. (1999), ‘normal’ breast tissues from patients with 
carcinoma were examined. Normal luminal and myoepithelial cell clones from 
cancerous patients were studied for LOH. LOH was identified in 5 of 10 breast 
cancer cases, in normal luminal and myoepithelial cells in regions both adjacent to 
and also distant from the tumour. The demonstration of genetic alteration in normal 
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 luminal and myoepithelial cells points out that these genetic alterations probably 
occur very early in breast development, further supporting the role of stem cells in 
breast cancer. 
               Another study by Smith and Boulanger (2002) demonstrated that local 
regions of serially transplanted mammary epithelium (transplantation in MMTV-
infected mice) occasionally manifested regions of hyperplastic lobular development. 
These lesions were proved to be clonal in origin by restriction enzyme (RE) digestion 
and repeatedly produced hyperplastic lobular mammary outgrowths on 
transplantation. Also, in their study, one normal fragment, a fourth-generation 
transplant, generated an aggressive mammary neoplasm and spawned several 
metastases to the lung. Both mammary and metastasized lung lesions were 
demonstrated to be clonal in origin. This study further confirms that premalignant 
and malignant clones may constitute a lineage potential of aging mammary stem 
cells.    
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CHAPTER II       AIM OF THE STUDY 
 
2.1 AIM 
               Organ-specific stem cells were described for most of the organs in our 
body. These stem cells are responsible for constituting the entire cellular population 
of the tissue, which are differentiated to perform specialized functions attributed for 
the organ. Recent studies have demonstrated the existence of stem/progenitor cells in 
mammary epithelium which give rise to the differentiated lineages of the mammary 
epithelium: luminal and myoepithelial cell lineages. Mammary carcinoma arises 
from the mammary epithelium. Studies have displayed that the differentiated 
mammary gland is less susceptible to breast carcinogenesis, therefore the putative 
stem/progenitor cells are more prone to acquire genetic alterations, leading to 
malignant transformation. Recent studies have supported this hypothesis, therefore it 
is proposed that the putative stem cells play an important role in breast 
carcinogenesis. 
               Our aim is to investigate whether our established breast cancer cell lines 
have stem cell-like property, that is, to demonstrate that the established breast cancer 
cell lines have derived from a stem/progenitor cell, in other words, that they are 
clonal in origin. Established breast cancer cell lines have been used in our study since 
they are devoid of any contamination of cells such as fibroblasts or blood cells.          
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 2.2 STRATEGY 
               We used six breast cancer cell lines (MCF-7, CAL-51, MDA-MB-175, 
GI-101, HBL-100 and 734-B) to study their marker protein expression of the breast 
epithelium by using indirect immunofluorescence. Five marker proteins (Cytokeratin 
19 (CK19), Cytokeratin 18 (CK18), Sialomucin (MUC1), Alpha-Smooth Muscle 
Actin (ASMA) and Epithelial Specific Antigen (ESA)) were used to specify the 
epithelial differentiation status of the cell lines in order to investigate any 
stem/progenitor cell-like property. Western Blotting was performed to further 
confirm the protein expression profile of the cell lines. To display the clonal origin of 
the cell lines, single cell culture of GI-101 cell line was performed and marker 
protein expression was demonstrated by using indirect immunofluorescence.   
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CHAPTER III        MATERIALS AND METHODS 
 
3.1 Tissue Culture 
               All cells (listed in Table 3-1) were grown as monolayer culture in 100-
mm or 150-mm culture dishes. The cells were grown in Dulbecco’s Medium 
(DMEM) supplemented with 10%FCS, 1% non-essential amino acids and 1% 
penicillin/streptomycin and were kept at 37°C and 5% CO2. 
 
3.1.1 Thawing of Cells 
               The vial of the frozen cell line from the liquid nitrogen tank was taken and 
immediately placed on ice. The vial was then placed at 37°C water bath until the 
frozen cell suspension was thawed. Then, the thawed cell suspension was transferred 
into 10 ml fresh medium (DMEM) in 15-ml Falcon tube. The cells were centrifuged 
at 1500 rpm for 5 minutes at 4°C.   Supernatant was discarded and the pellet was 
resuspended in 10 ml fresh DMEM and the cell suspension was placed in 100-mm 
dish. Cells were left overnight in culture. The medium was refreshed on the 
following morning.  
 
3.1.2 Subculturing of Cells 
               Culture renewal was performed every two or three days. Cells were 
splitted when they reached 80-90% confluency. For splitting, the medium was 
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 aspirated and the cells were washed with sterile PBS (pH: 7.4) for twice. PBS was 
removed and trypsin was added to the plates. Plates were incubated in the incubator 
for 5-10 minutes until the cells were detached. Cells were plated in the desired 
dilution into new plates.  
3.1.3 Freezing of Cells  
               The cells to be frozen were grown in a 150-mm cell culture dish to 70-80% 
confluency. The cells were washed twice with PBS, trypsinized and placed in the 
incubator until they were detached. The unattached cells were collected with 10 ml 
fresh DMEM. The cell suspension was centrifuged at 1500 rpm for 5 minutes and the 
supernatant was discarded. The cells were resuspended in 1.5 ml freezing medium 
containing 20% FCS, 10% DMSO, 70% DMEM and the cell suspension was placed 
in a vial. The vial was immediately placed in -20°C, and was kept for 3 hours at this 
temperature. Then, the vial was moved to -80°C and was kept for o/n at this 
temperature and transferred to liquid nitrogen tank on the following day. 
 
Table 3.1 The cell lines used in this study (All the cell lines studied were of human 
origin and were grown in DMEM medium) 
     NAME         TISSUE                             DESCRIPTION 
     MCF-7       Breast Cancer From a 69-year-old Caucasian female, differentiated 
adenocarcinoma origin, estrogen receptor-(+) 
     CAL-51     Breast Cancer From the pleural effusion metastasis of a 45-year-old 
female, adenocarcinoma origin, no viral infection 
 MDA-MB-175     Breast Cancer From a 56-year-old Black female, pleural effusion 
ductal carcinoma origin, tumor formation in nude 
mice  
     GI-101     Breast Cancer Established in 1985, recurrent infiltration ductal 
carcinoma origin, poorly differentiated, estrogen 
receptor-(+) 
    HBL-100           Breast  From the milk of a 27-year-old Caucasian nursing 
female, viral infection by SV40  
      734-B     Breast Cancer Established subclone of MCF-7 cell line 
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3.2 Single Cell Cloning  
               The cells grown in 50-mm dishes were washed with PBS twice and then 
trypsinized. The detached cells were collected by using 10 ml fresh DMEM and were 
counted by using cytometer. Serial dilutions were performed to approximate the 
optimum concentration of 1 cells/1 well by using fresh DMEM. Then cells were 
seeded in 24- or 96-well plates in desired amounts and carefully examined after 
seeding and in the following days whether single cell is present in each well. 
Medium of cells were refreshed once a week. Upon reaching the desired confluency, 
cells were transferred to 24-, 6-well plates and 60-mm dish in order. When cells were 
grown until desired confluency in 60-mm dish, they were seeded on the autoclaved-
sterilized coverslips which were placed in the wells of 6-well plates. After 2 days, 
indirect immunofluorescence of the cells was performed, as described below. 
 
3.3 Indirect Immunofluorescence Staining 
               Cells were seeded on the autoclaved-sterilized coverslips which were 
placed into the well of 6-multiwell plates at the concentration of 100.000 cells/ml 
after washing with PBS, trypsinization and counting and were grown for 4 days in 3 
ml DMEM. Cells were washed with PBS three times after medium aspiration and 
then were fixed with ice-cold methanol at +4°C for 5 min, and blocked against non-
specific binding with PBS containing 10% FCS for 30 min. Then cells were 
incubated with monoclonal mouse anti-CK19 (1: 500) (Santa Cruz/ sc-6278), mouse 
anti-CK18 (1: 500) (a gift from D.Bellet, France), mouse anti-ESA (1: 500) (Sigma / 
E-6011), mouse anti-ASMA (1: 100) (ABCAM / ab7817-500) or mouse anti-MUC 
(1: 100) (ABCAM / ab8607-250) antibody diluted in PBS containing 1.5% FCS for 
60 min. After washing with PBS three times with 5 min intervals, cells were 
incubated with FITC-conjugated anti-mouse (DAKO / F-0479) (1: 200) secondary 
antibody diluted in PBS containing 1.5% FCS for 45 min. Beginning from this step, 
the procedure was performed under dark. After washing with PBS three times with 5 
min intervals, nuclear DNA was stained with DAPI or Hoechst 33258 for 5 min. 
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 DAPI or Hoechst 33258 was aspirated and destaining was performed in double-
distilled water for 5 min. Coverslips were taken out from the well and excess water 
was removed by tissue paper, coverslips were mounted onto slides containing 12 µl 
80% glycerol. Each immunostaining experiment was done using negative controls 
(no first antibody). Stained cells were examined under fluorescence microscope 
(ZEISS) and pictures were captured in a digital Kodak Camera (DC290, Eastman 
Kodak Co.), using Adobe Photo Deluxe (Adobe Systems Inc.) software. Pictures 
were processed using Adobe Photoshop 5.0 (Adobe Systems Inc.) software. 
 
Phosphate-Buffered Saline (PBS) 
10 X Stock Solution (1 lt)                                   Working Solution (pH: 7.3-7.6)    
80 g NaCl, 2g KCl,                                              10X  PBS diluted to 1X with                                      
11.5 g Na2HPO4.7H2O, 2 g KH2PO4                             ddH2O 
DAPI Staining 
• 1 mg DAPI was dissolved in 1 ml double-distilled water (Stock Solution – kept at 
-20°C) 
• 10 µl stock solution was diluted in 100 ml 1X PBS. (Working Solution – kept at 
room temperature) 
Hoechst Staining 
• Hoechst 33258 stock solution was diluted 250 times with ddH2O 
 
3.4 Immunoblotting 
3.4.1 Crude Total Protein Extraction from Cultured Cells 
               Cells were grown to 70-80% confluency and were washed with ice-cold 
PBS once. Then, cells were scraped in ice-cold PBS and centrifuged at 1500 rpm for 
5 minutes at 4°C. The supernatant was discarded, cell pellets were stored at -80°C for 
                                                                                                                                                                 34
   
  
 further analysis. Pellets were then lysed immediately in NP-40 lysis buffer, which 
was prepared freshly just before use. For lysis, the pellets were resuspended in 4 
volume of NP-40 lysis buffer and were incubated on ice for 30 minutes by stirring 
the cell within 10 minutes periods. The lysate was then centrifuged at 13000 rpm for 
5 minutes at 4°C. Supernatant was then aliquoted into fresh Eppendorf tubes, stored 
at -80°C and some amount was also taken for protein quantitation.  
NP-40 Lysis Buffer (1 ml) 
50 µl 1 M Tris (pH 8.0) 
125 µl 2 M NaCl 
10 µl NP-40 
40 µl 25X Protease Inhibitor (Tablet dissolved in 2 ml sterile ddH2O) (Sigma) 
775 µl ddH2O 
 
3.4.2 Bradford Assay for Protein Quantification 
               Stock Bovine Serum Albumin (BSA) was prepared as in concentration 1.0 
mg/ml and was kept at -20°C. Different dilutions of BSA was prepared as described 
below: 
 
Tube numbers 1 2 3 4 5 6 7 
BSA stock (µl) 0 1 2 4 8 16 32 
ddH2O (µl) 100 99 98 96 92 84 68 
Bradford Working(µl) 900 900 900 900 900 900 900 
 
Protein samples were prepared as described below: 
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 Tube numbers 1 2 3 4 5 6 7 
Sample (µl) 0 2 2 2 2 2 2 
ddH2O (µl) 98 98 98 98 98 98 98 
Bradford Working(µl) 900 900 900 900 900 900 900 
Lysis Buffer (µl) 2 - - - - - - 
 (1 = blank in both tables) 
               Blanks, BSA standards, test samples were prepared in disposable plastic 
cuvettes. The absorbance of each sample was measured at 595 nm using a UV-
visible spectrophotometer. The absorbance of each BSA standard was plotted 
linearly as a function of its theoretical concentration and best straight line was drawn 
in the form of the equation “y = mx + b” where y = absorbance at 595 nm and x = 
protein concentration. This equation was used to calculate the concentration of the 
protein samples based on the measured absorbance.  
 
Bradford Stock Solution                                Bradford Working Solution  
17.5 mg SERVA Blue G                          85 ml ddH2O                             
10 ml 88 % phosphoric acid                            3 ml 95 % ethanol 
5 ml 95 % ethanol                                            6 ml 88 % phosphoric acid  
250 ml ddH2O                                                  6 ml Bradford stock solution 
Both solutions were kept in a brown bottle at +4°C. 
 
3.4.3 SDS-Polyacrylamide Gel Electrophoresis of Proteins 
               The glass plates were assembled according to manufacturer’s instructions 
(CBS). The volume of the gel mold was determined according to the information 
provided by the manufacturer (CBS). In a Falcon tube, the appropriate volume of 
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 solution containing the desired concentration of acrylamide for the resolving gel was 
prepared. Effective range of separation of SDS-PAGE gels due to different 
acrylamide concentrations are summarized in Table 3.2. In this study, 10% resolving 
gel was used and the concentrations of its components are described in Table 3.3. 
Table 3.2 Effective range of separation of SDS-PAGE gels 
   Acrylamide concentration (%)      Linear range of separation (kD) 
                   15                     12-43                              
                   10                     16-68 
                  7.5                     36-94 
                  5.0                    57-212 
                
               TEMED was added to the gel solution for polymerization just before the gel 
was cast. The mixture was swirled rapidly without delay. Then, the resolution SDS-
PAGE gel solution was poured into the gap between the glass plates. Sufficient space 
for stacking gel was left. Immediately, 100% isopropanol was overlaid onto 
resolution SDS-PAGE gel using a Pasteur pipette. The gel was placed in a vertical 
position to polymerize at room temperature. An aliquot of resolution gel was kept to 
check polymerization. After polymerization was complete, the overlaying 
isopropanol was poured off and the top of the gel was washed several times with 
distilled water. Any remaining water was removed with the edge of a paper towel. 
Then, 5% stacking SDS-PAGE gel solution was prepared in a Falcon tube, TEMED 
was added for polymerization just before the gel was cast. The concentrations of the 
components of the 5 % stacking gel are described in Table 3.4. The mixture was 
swirled rapidly without delay. Then, the stacking SDS-PAGE gel solution was 
poured directly onto the surface of the polymerized resolution SDS-PAGE gel. A 
clean comb was inserted immediately into the SDS-PAGE gel solution, it was 
avoided trapping air bubbles. To fill the spaces of the comb completely, more 
stacking SDS-PAGE gel solution was added. The gel was placed in a vertical 
                                                                                                                                                                 37
   
  
 position at room temperature. An aliquot of stacking gel was kept to check 
polymerization.  
               While the stacking gel was polymerizing, the samples to be loaded were 
prepared by heating them to 100°C for 5 minutes in 1X SDS gel-loading buffer to 
denaturate the proteins. Then, the heated protein lysate/SDS gel loading buffer 
mixtures were immediately placed on ice and were incubated for 5 min. After 
polymerization was complete, the comb was removed carefully. The wells were 
washed with distilled water to remove any unpolymerized acrylamide. The gel was 
mounted in the electrophoresis apparatus. 1X Tris-glycine electrophoresis buffer was 
added to the top and bottom reservoirs. Then 30-50 µg of the protein lysates and the 
marker proteins of known molecular weight were loaded in a predetermined order 
into the bottom of the wells. The electrophoresis apparatus was attached to an 
electrophoresis supply and the gel was run at 80 Volts until the dye front has moved 
to the resolving gel, later the voltage was increased to 120 Volts, until the 
bromophenol blue reaches the bottom of the resolving gel. Then the power supply 
was turned off. The glass plates were removed from the electrophoresis apparatus 
and were placed on a paper towel. By using a spatula, the plates were separated from 
each other. Orientation of the gel was marked by cutting a corner from the top of the 
gel. 
Tris-Glycine Electrophoresis Buffer (5X) 
22.5 g Tris                      Volume was then adjusted to 1500 ml with ddH2O,    
108 g Glycine                 stored at 4°C, diluted to 1X with ddH2O when used.  
7.5 g SDS                       
750 ml ddH2O.                                     
30 % mix (Acrylamide and bis-acrylamide solution) 
29.2 g acrylamide                 Volume was adjusted to 100 ml with ddH2O, filter  
0.8 g Bis-acrylamide             sterilized, stored at 4°C in dark bottles. 
70 ml ddH2O 
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 10% SDS 
A 10% (w/v) stock solution was prepared in ddH2O. 
APS 
A small amount of 10% stock solution was prepared freshly in ddH2O. 
5X Gel Loading Buffer 
3.8 ml ddH2O 
1.0 ml 0.5 M Tris-HCl 
0.8 ml glycerol 
1.6 ml 10% SDS 
0.4 ml 0.05% BPB fluid 
400 µl β-Mercaptoethanol (added freshly)          
 
Table 3.3 Components of 10% resolving gel for Tris-Glycine SDS-PAGE 
Solution components                                 Component Volumes (ml) 
10% 5 ml 10 ml 15 ml 20 ml 25 ml 30 ml 40 ml 50 ml 
ddH2O 1.9 4.0 5.9 7.9 9.9 11.9 15.9 19.8 
30% mix 1.7 3.3 5.0 6.7 8.3 10.0 13.3 16.7 
1.5 M Tris (pH 8.8) 1.3 2.5 3.8 5.0 6.3 7.5 10.0 12.5 
10% SDS 0.05 0.1 0.15 0.20 0.25 0.30 0.40 0.50 
10% APS 0.05 0.1 0.15 0.20 0.25 0.30 0.40 0.50 
TEMED 0.002 0.004 0.006 0.008 0.010 0.012 0.016 0.020 
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 Table 3.4 Components of 5% stacking gel for Tris-Glycine SDS-PAGE 
Solution components                                    Component Volumes (ml) 
10% 1 ml 2 ml 3 ml 4 ml 5 ml 6 ml 8 ml 10 ml 
ddH2O 0.68 1.4 2.1 2.7 3.4 4.1 5.5 6.8 
30% mix 0.17 0.33 0.50 0.67 0.83 1.0 1.3 1.7 
1.0 M Tris (pH 6.8) 0.13 0.25 0.38 0.50 0.63 0.75 1.0 1.25 
10% SDS 0.01 0.02 0.03 0.04 0.05 0.06 0.08 0.1 
10% APS 0.01 0.02 0.03 0.04 0.05 0.06 0.08 0.1 
TEMED 0.001 0.002 0.003 0.004 0.005 0.006 0.008 0.01 
 
3.4.4 Transfer of Proteins from SDS-polyacrylamide Gels to Solid Supports 
            When the SDS-polyacrylamide gel was approaching the end of its run, four 
pieces of Whatman 3MM paper and one piece of transfer membrane (PVDF) was cut 
as the exact size of the SDS-polyacrylamide gel by wearing gloves. The membrane 
was left in methanol for 1 minute and then was soaked into transfer buffer for 10-15 
minutes. Meanwhile, the Whatman 3MM papers were soaked into a shallow tray 
containing a small amount of transfer buffer and were kept shaking for 1 minute. 
              The transfer apparatus was set as follows: 
1. 2 pieces of Whatman 3MM paper that have been soaked in transfer buffer 
were placed onto the plate which will be positively charged (anode). All 
air bubbles were squeezed. 
2. The PVDF membrane was placed onto the Whatman 3MM papers. (The 
transfer membrane should be exactly aligned and the air bubbles trapped 
between it and the Whatman 3MM paper were squeezed out.) 
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 3. The glass plates holding the SDS-polyacrylamide gel were removed from 
the electrophoresis tank, and the gel was transferred to a tray of transfer 
buffer and was kept there for 10 minutes. 
4. Then SDS-polyacrylamide gel was placed onto the transfer membrane. 
Any trapped air bubbles were squeezed out. 
5. 2 pieces of Whatman 3MM paper were placed to the top of the sandwich 
(this side will be negatively charged during the transfer (cathode side)).                            
             The electrical leads of the apparatus were connected to the power supply and 
the transfer was carried out at a current of 3 mA/cm2 of the gel for 45 minutes. The 
electric current was turned off at the end of the run time and the transfer apparatus 
was disassembled from top downward, peeling off each layer in turn. The positions 
of wells and pre-stained marker were marked using a needle or a pin. Also, the top 
left-hand corner of the membrane was cut for orientation purpose. 
Transfer Buffer    
2.9 g Glycine                          Volume was then adjusted to 1 lt with ddH2O 
5.8 g Trisma base                        
0.37 g SDS 
200 ml methanol 
 
3.4.5 Immunological Detection of Immobilized Proteins (Western Blotting) 
             The membrane was then immersed in the blocking solution which contains 
3% milk powder in 0.1% Tween-TBS solution for one hour on a rotating platform. 
Then the membrane was incubated with primary antibody (Table 3.5), which has 
been diluted according to instructions in blocking solution, for one hour at room 
temperature or at 4°C overnight on a slowly rotating platform. Later, the membrane 
was washed for four times, once for 10 minutes, and three times for 5 minutes, with 
TBS-T. After the washing, the membrane was incubated with a secondary antibody 
HRP-conjugated anti-mouse Ig (ABCAM / ab6728-1), which is diluted as 1:3500 in 
blocking solution for 1 hour at room temperature on a slowly rotating platform. The 
                                                                                                                                                                 41
   
  
 membrane was then washed with TBS-T for four times, once for 10 minutes, and 
three times for 5 minutes. The membrane becomes ready for incubation with 
substrate and development. After the detection of proteins, membrane was further 
used for loading control. The primary antibody rabbit anti-calnexin (Sigma/C-4731) 
diluted in blocking solution was used as the loading control. The HRP-conjugated 
anti-rabbit Ig (DAKO / P-0448) (1:2500 diluted in blocking solution) was used as the 
secondary antibody. All primary and secondary incubations and washings were 
performed as described above.  
Table 3.5 The primary antibodies used in this study for Western blotting  
Company Origin Against/Clone name Clonality Dilution 
Santa Cruz Mouse Cytokeratin 19/A53-B/A2 Monoclonal 1:1000 
* Mouse Cytokeratin 18/JAR13 Monoclonal 1:5000 
Sigma Mouse ESA/VU-1D9 Monoclonal 1:1000 
Sigma Rabbit Calnexin Monoclonal 1:5000 
* Kindly provided by D.Bellet, France 
             For detection, either ECL (Enhanced ChemiLuminescence; Amersham 
Pharmacia Biotech. Cat. No. RPN 2106) or LumiLight (Roche Diagnostics GmbH. 
Cat No. 2 015 200) detection systems were carried out according to manufacturer’s 
instructions.   
 
Tris-Buffered Saline (TBS) (10X) 
24.2 g Tris-Base            Volume was adjusted to 1lt with ddH2O. TBS was   
80 g NaCl                      diluted to 1X with ddH2O before use (pH: 7.6).  
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CHAPTER IV    RESULTS 
 
4.1 Characterization of Breast Cancer Cell Lines by Marker Antibodies  
             To investigate whether breast cancer cell lines display stem cell-like 
property, the 6 breast cancer cell lines were characterized in terms of marker protein 
expression which describes the epithelial differentiation status of the cell. 
Immunofluorescence of 6 breast cancer cell lines with 5 marker antibodies was 
performed as described in “Materials and Methods” section. Western Blotting was 
done to further confirm the protein expression. The marker proteins that were used in 
our study and their expression in terms of mammary epithelial differentiation status 
are described in Table 4.1. 
 
Table 4.1 Marker proteins of mammary epithelial cells used in this study and their 
expression in terms of differentiation status  
Marker Proteins                    Differentiation Status                References 
 Stem/  
Progenitor 
Cell 
Differentiated 
Luminal 
Epithelial Cell 
Differentiated 
Myoepithelial 
Cell 
 
Cytokeratin 19 (CK19)         +         +/-          - Gudjonsson et al., (2002), 
Taylor-Papadimitriou et al., 
(1989) 
Cytokeratin 18 (CK18)        -/+          +          - Taylor-Papadimitriou et al., 
(1989), Pechoux et al. (1999) 
Epithelial Specific 
Antigen (ESA) 
        +          +          - Gudjonsson et al., (2002), 
Stingl et al., (1998) 
Sialomucin (MUC1)         -          +          - Gudjonsson et al., (2002), 
Stingl et al., (1998) 
Alpha-Smooth Muscle 
Actin (ASMA) 
        -          -          + Gudjonsson et al., (2002), 
Petersen and van Deurs, 
(1988) 
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 4.1.1 Indirect Immunofluorescence of Breast Cancer Cell Lines 
4.1.1.1 Staining of Cell Lines with anti-CK19 antibody 
             6 breast cancer cell lines (MCF-7, CAL-51, MDA-MB-175, GI-101, HBL-
100, 734-B) were grown on coverslips and immunofluorescence of these cell lines 
was performed by using anti-CK19 antibody. Counterstaining with DAPI displayed 
that MCF-7 and 734-B were positive; CAL-51, MDA-MB-175 and GI-101 were 
heterogenous; HBL-100 was negative for cytoplasmically expressed CK19 antigen 
(Figure 4.1). 
             MCF-7                           CAL-51                          MDA-MB-175             
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Figure 4.1 Immunofluorescence staining of breast cancer cell lines with anti-CK19 
antibody. (CK19 staining: MCF-7 (A), CAL-51 (E), MDA-MB-175 (I), GI-101 (M), 
HBL-100 (R), 734-B (V). DAPI staining: MCF-7 (B), CAL-51 (F), MDA-MB-175 
(J), GI-101 (N), HBL-100 (S), 734-B (W). Merged images: MCF-7 (C), CAL-51 (G), 
MDA-MB-175 (K), GI-101 (O), HBL-100 (T), 734-B (Y). Negative control (with no 
primary antibody): MCF-7 (D), CAL-51 (H), MDA-MB-175 (L), GI-101 (P), HBL-
100 (U), 734-B (Z).)    
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 4.1.1.2 Staining of Cell Lines with anti-CK18 antibody 
             6 breast cancer cell lines (MCF-7, CAL-51, MDA-MB-175, GI-101, HBL-
100, 734-B) were grown on coverslips and immunofluorescence of these cell lines 
was performed by using anti-CK18 antibody. Counterstaining with DAPI displayed 
that all cell lines except CAL-51 was positive for cytoplasmically expressed CK18, 
while CAL-51 was heterogenous for CK18 (with approximately 95% positivity) 
(Figure 4.2). 
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Figure 4.2 Immunofluorescence staining of breast cancer cell lines with anti-CK18 
antibody. (CK18 staining: MCF-7 (A), CAL-51 (E), MDA-MB-175 (I), GI-101 (M), 
HBL-100 (R), 734-B (V). DAPI staining: MCF-7 (B), CAL-51 (F), MDA-MB-175 
(J), GI-101 (N), HBL-100 (S), 734-B (W). Merged images: MCF-7 (C), CAL-51 
(G), MDA-MB-175 (K), GI-101 (O), HBL-100 (T), 734-B (Y). Negative control 
(with no primary antibody): MCF-7 (D), CAL-51 (H), MDA-MB-175 (L), GI-101 
(P), HBL-100 (U), 734-B (Z).)    
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 4.1.1.3 Staining of Cell Lines with anti-ESA antibody 
 
               6 breast cancer cell lines (MCF-7, CAL-51, MDA-MB-175, GI-101, HBL-
100, 734-B) were grown on coverslips and immunofluorescence of these cell lines 
was performed by using anti-ESA antibody. Counterstaining with DAPI displayed 
that 734-B cell line was positive; but with varying intensity, HBL-100 cell line was 
negative; all the other cell lines displayed heterogeneity for peripherally expressed 
ESA antigen (with approximately 80% positivity) (Figure 4.3).  
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Figure 4.3 Immunofluorescence staining of breast cancer cell lines with anti-ESA 
antibody. (ESA staining: MCF-7 (A), CAL-51 (E), MDA-MB-175 (I), GI-101 (M), 
HBL-100 (R), 734-B (V). DAPI staining: MCF-7 (B), CAL-51 (F), MDA-MB-175 
(J), GI-101 (N), HBL-100 (S), 734-B (W). Merged images: MCF-7 (C), CAL-51 
(G), MDA-MB-175 (K), GI-101 (O), HBL-100 (T), 734-B (Y). Negative control 
(with no primary antibody): MCF-7 (D), CAL-51 (H), MDA-MB-175 (L), GI-101 
(P), HBL-100 (U), 734-B (Z).)    
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 4.1.1.4 Staining of Cell Lines with anti-MUC1 antibody 
             6 breast cancer cell lines (MCF-7, CAL-51, MDA-MB-175, GI-101, HBL-
100, 734-B) were grown on coverslips and immunofluorescence of these cell lines 
was performed by using anti-MUC1 antibody. Counterstaining with DAPI or 
Hoechst displayed that 734-B (displaying 20% positivity) and MCF-7 were 
heterogenous (displaying 5% positivity); all the other cell lines were negative for 
peripherally expressed MUC1 antigen (Figure 4.4). 
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Figure 4.4 Immunofluorescence staining of breast cancer cell lines with anti-MUC1 
antibody. (MUC staining: MCF-7 (A), CAL-51 (E), MDA-MB-175 (I), GI-101 (M), 
HBL-100 (R), 734-B (V). Counterstaining (DAPI unless otherwise stated): MCF-7 
(B), CAL-51 (F), MDA-MB-175 (J), GI-101 (Hoechst) (N), HBL-100 (S), 734-B 
(W). Merged images: MCF-7 (C), CAL-51 (G), MDA-MB-175 (K), GI-101 (O), 
HBL-100 (T), 734-B (Y). Negative control (with no primary antibody): MCF-7 (D), 
CAL-51 (H), MDA-MB-175 (L), GI-101 (P), HBL-100 (U), 734-B (Z).)    
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4.1.1.5 Staining of Cell Lines with anti-ASMA antibody 
             6 breast cancer cell lines (MCF-7, CAL-51, MDA-MB-175, GI-101, HBL-
100, 734-B) were grown on coverslips and immunofluorescence of these cell lines 
was performed by using anti-ASMA antibody. Counterstaining with DAPI displayed 
that only GI-101 (displaying 30% positivity) was heterogenous and all the other cell 
lines were negative for cytoplasmically expressed ASMA antigen (Figure 4.5). 
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Figure 4.5 Immunofluorescence staining of breast cancer cell lines with anti-ASMA 
antibody. (ASMA staining: MCF-7 (A), CAL-51 (E), MDA-MB-175 (I), GI-101 
(M), HBL-100 (R), 734-B (V). DAPI staining: MCF-7 (B), CAL-51 (F), MDA-MB-
175 (J), GI-101 (N), HBL-100 (S), 734-B (W). Merged images: MCF-7 (C), CAL-51 
(G), MDA-MB-175 (K), GI-101 (O), HBL-100 (T), 734-B (Y). Negative control 
(with no primary antibody): MCF-7 (D), CAL-51 (H), MDA-MB-175 (L), GI-101 
(P), HBL-100 (U), 734-B (Z).)    
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4.1.2 Western blotting of Breast Cancer Cell Lines 
                        
             6 cancer cell lines (MCF-7, CAL-51, MDA-MB-175, GI-101, HBL-100, 
734-B) were grown up to desired confluency in 100-mm and 150-mm dishes. Then, 
cell pellets were collected by a scraper. From the cell pellets, cell lysates were 
prepared by using NP-40 lysis buffer. This total cell lysate was then loaded to 10% 
SDS-PAGE. Afterwards, proteins were transferred to PVDF membranes and then 
these membranes were subjected to Western blotting as described in “Materials and 
Methods” section by using the antibodies of marker proteins.    
 
4.1.2.1 Western Blotting by anti-CK19 antibody 
                          
             Total cell lysates of 6 cancer cell lines (MCF-7, CAL-51, MDA-MB-175, 
GI-101, HBL-100, 734-B) were subjected to Western blotting by using anti-CK19 
antibody. HBL-100 displayed no CK19 band, on the other hand, GI-101 and CAL-51 
displayed weaker CK19 bands than the strong CK19 bands of MCF-7, MDA-MB-
175 and 734-B cell lines. Anti-calnexin antibody was used as loading control (Figure 
4.6). 
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  Figure 4.6 Western Blotting patterns of breast cancer cell lines by anti-CK19   
  antibody 
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4.1.2.2 Western Blotting by anti-CK18 antibody 
                          
             Total cell lysates of 6 cancer cell lines (MCF-7, CAL-51, MDA-MB-175, 
GI-101, HBL-100, 734-B) were subjected to Western blotting by using anti-CK18 
antibody. All cell lines displayed intense CK18 bands, therefore anti-calnexin 
staining was not necessitated as loading control (Figure 4.7).  
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 Figure 4.7 Western Blotting patterns of breast cancer cell lines by anti-CK18  
 antibody      
                 
4.1.2.3 Western Blotting by anti-ESA antibody 
  
               Total cell lysates of 3 cancer cell lines (MCF-7, CAL-51, MDA-MB-175) 
were subjected to Western blotting by using anti-ESA antibody. All three cell lines 
displayed ESA bands, while the ESA band of CAL-51 was very weak. Anti-calnexin 
antibody was used as loading control (Figure 4.8). 
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Figure 4.8 Western Blotting patterns of breast cancer cell lines by anti-ESA  
antibody      
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4.1.3 Classification of Breast Cancer Cell Lines according to Marker Protein 
Expression 
                         
               Based on these results, breast cancer cell lines have been classified 
according to marker protein expression in terms of mammary epithelium 
differentiation status. This classification is indicated in Table 4.2. The numbers in 
parenthesis display the percentage of positivity for marker protein expression in 
heterogenous cell populations. 
 
Table 4.2 Classification of Breast Cancer Cell Lines according to Marker Protein 
Expression in terms of Mammary Epithelium Differentiation Status 
                                                     Cell Lines  
  Marker 
  Protein    MCF-7    CAL-51  MDA-MB-175 
           
  GI-101  HBL-100    734-B 
   CK18         +  Het (95%)            +       +        +       + 
   CK19         +  Het (50%)     Het (50%) Het (50%)        -       + 
     ESA  Het (80%)  Het (80%)     Het (80%) Het (80%)        -       + 
    MUC1   Het (5%)         -           -        -        - Het (20%) 
    ASMA         -         -           - Het (30%)        -        - 
 
Het: Heterogenous 
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4.2 Single cell cloning of GI-101 cell line and Immunofluorescence Analysis 
                        
               Our immunofluorescence analysis of cell lines have revealed that GI-101 
cell line displayed that this cell line contains heterogenous cell populations in terms 
of marker protein expression associated with mammary epithelium differentiation 
status. To investigate whether these heterogenous populations are clonal in origin, 
i.e. one cell gives rise to different types of cell populations which means that this cell 
line has stem/progenitor cell property, single-cell cloning of GI-101 cell line was 
performed as described in “Materials and Methods” section. A single cell is 
displayed on a well of 96-well plate in Figure 4.9. After growth of colonies derived 
from a single clone in 24-well, 6-well and 60-mm plates until the desired confluency, 
immunofluorescence of the colonies was performed as described in “Materials and 
Methods” section by using anti-CK18, anti-CK19, anti-ESA, anti-ASMA marker 
antibodies. The results have displayed that the phenotypic CK-19-, ESA-, ASMA-
heterogenous populations (ASMA-positivity is low) are clonal in origin, i.e. they 
were derived from a single cell, which means that GI-101 cell line has 
stem/progenitor cell property. The colonies also displayed CK-18-positive pattern. 
The immunofluorescence results are displayed in Figure 4.10. 
 
              
 
                       Figure 4.9 Single cell in 1 well of 96-well plate  
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Figure 4.10 Immunofluorescence staining patterns of GI-101 colonies derived from a single        
clone. (anti-ASMA & DAPI stainings & merged image (A,B,C); anti-CK19 & DAPI stainings & 
merged image (D,E,F); anti-ESA & DAPI stainings & merged image (G,H,I);  anti-CK18 & DAPI 
stainings & merged image (J,K,L); Negative control (no primary antibody) (M))  
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CHAPTER V    DISCUSSION AND FUTURE PERSPECTIVES 
 
               
              In this study, breast cancer cell lines were classified according to marker 
protein expression in terms of mammary epithelium differentiation status. 
Immunofluorescence and Western blotting methods were used for this 
characterization. The marker proteins used in this study were CK18, CK19, ESA, 
MUC1 and ASMA. Therefore, whether these cell lines have stem/progenitor cell 
property was investigated by examining from which differentiation status the cell 
lines may have originated. The classification was displayed in Table 4.2.  
 
              Almost all the cell lines (CAL-51 with 95% positivity) displayed CK-18-
(+) phenotypic profile, notifying that the cell lines originated from luminal or at 
least, basoluminal part of the epithelium, not from the basomyoepithelial part of the 
epithelium. %5 CAL-51 CK-18-(-) population would be a candidate for 
basomyoepithelial origin if CAL-51 expressed ASMA marker protein. 
 
              The CK-19-(+), ESA-Het (with 80% positivity) phenotypic profile makes 
MCF-7 cell line a strong candidate for stem/progenitor cell property. MUC1-Het 
(with 5% positivity) and ASMA-(-) phenotype describes that MCF-7 cell line most 
probably has originated from an intermediate progenitor cell of luminal 
differentiation. Therefore, it seems likely that this cell line represents a more 
differentiated status than CAL-51 and MDA-MB-175 cell lines. 
 
              734-B almost has the same phenotypic profile as MCF-7 cell line. On the 
other hand, ESA and MUC1 positivity is higher than MCF-7 cell line, displaying 
that 734-B most probably has originated from an intermediate, but more 
differentiated than MCF-7 cell line, progenitor cell of luminal differentiation.  
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               HBL-100, as a breast cell line derived from milk of a nursing woman, 
displayed a very interesting profile of marker protein expression. This cell line is 
positive for only CK-18 marker protein, the other marker proteins were not 
expressed. Therefore, any precise conclusion of the origin of this cell line cannot be 
drawn, only it can be considered that this cell line is luminal in origin. 
 
              GI-101 displayed a remarkable phenotypic profile. The heterogenous 
expression patterns of CK-19, ESA and ASMA demonstrate that this cell line 
represent progenitor cell populations in different stages of differentiation. ASMA-
heterogeneity describes that these stages are most probably intermediates of 
myoepithelial differentiation. Double immunofluorescence analysis of CK19, ESA 
and ASMA marker proteins will display a more precise description of origin of this 
cell line. For instance, the presence of any CK19(-)-ASMA-(+) cell population 
would represent a differentiated myoepithelial origin, CK-19-(+)-ASMA-(+) cell 
population would represent an intermediate step of myoepithelial differentiation, 
whereas CK-19-(+)-ASMA-(-) would represent a progenitor cell population in a less 
differentiated state. Single cell cloning of this cell line also further supported that 
this cell line has stem/progenitor cell property, which is described in detail below. 
Also, low density growth of this cell line was performed on Matrigel as a basement 
membrane, after cultivation for approximately for 20 days, the cells gave rise to 
three-dimensional structures, though not defined precisely but examined under 
confocal microscope, has revealed that this cell line is a strong candidate for 
stem/progenitor cell-like property (data not shown). The same structures were not 
observed for MCF-7 cell line (data not shown).  
 
              CAL-51 and MDA-MB-175 displayed almost the same phenotypic profile 
of marker protein expression. The absence of MUC and ASMA protein expression, 
which represent terminally differentiation status, and the presence of CK-19 and 
ESA-heterogenous cell populations make these cell lines strong candidates for 
stem/progenitor cell-like property. These cell lines most probably have originated 
from progenitor cells in much less differentiated states than MCF-7, GI-101 and 
734-B cell lines, therefore their origin is much closer to a stem cell in terms of 
mammary epithelial differentiation. 
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               In conclusion, it can be considered that all cell lines examined in this study 
display, in varying degrees, stem/progenitor cell-like protein expression, with the 
possibility of dedifferentiation of the cell lines in in vitro conditions and the 
possibility of any phenotypic instability related with genomic instability is not 
excluded. All cell lines do not express MUC1 or ASMA, which are representatives 
of terminally epithelial differentiation status, showing that the cell lines have most 
probably originated, at least, from progenitor cells of intermediate steps of terminal 
mammary gland differentiation.   
 
              To further support the hypothesis that breast cancer cell lines have 
stem/progenitor cell property, single cell cloning of GI-101 cell line was performed 
to display that the heterogenous populations observed with indirect 
immunofluorescence with marker protein antibodies were clonal in origin. The 
colonies derived from a single clone were subjected to indirect immunofluorescence 
with marker protein antibodies of CK19, ASMA, ESA and CK18. The colonies 
displayed the same pattern of marker protein expression (CK-19-Het, ASMA-Het, 
ESA-Het, CK-18-(+)) as their ancestral cells, demonstrating that the heterogenous 
cell lines are clonal in origin, i.e. a single cell has given rise to different types of 
cells. That is, GI-101 has the properties of differentiation into new cell types and 
self-renewal, therefore, it can be concluded that, with some precautions, all the cell 
lines display stem/progenitor cell-like property. 
                       
              To draw more precise conclusions about from which differentiation status 
the breast cell lines may have originated, more markers can be used for analysis 
such as Cytokeratin 5, vimentin and CALLA.  
 
              The cell lines can also be cultivated in three-dimensional contexts such as 
collagen, laminin and Matrigel, by performing single cell cloning. The capability of 
the cell lines to form structures resembling ducts or alveoli can be tested by this 
approach. Therefore, the differentiation potential of the cell lines is to be examined. 
Our preliminary studies with GI-101 cell line on Matrigel have revealed that this 
cell line may have differentiation potential to form ductal/alveolar structures.  
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               Cancer, together with deregulated cellular proliferation, also originates due 
to blockage of differentiation of a cell. Therefore, it can be considered that the 
established breast cancer cell lines have defects in pathways which determine cell 
fates, that is, blockage of luminal and myoepithelial cellular differentiation results in 
breast carcinoma. The roles of Erb-B (Troyer and Lee, 2001), Wnt (Smalley and 
Dale, 2001), Notch (Callahan and Rafaet, 2001), Hedgehog (Lewis, 2001), TGF-β 
(Wakefield et al., 2001) signaling pathways and STAT (Watson, 2001) and ETS 
(Shepherd and Hassell, 2001) transcription factors in mammary gland development 
are currently being studied. The breast cancer cell lines can be studied in terms of 
these pathways and transcription factors so that more precise description of the 
origin of the breast cancer cell lines can be made. 
 
              Elucidation of the role of stem/progenitor cells in breast cancer and also 
their isolation would lead to the development of much more effective therapeutic 
approaches which target directly these cells, so that the breast cancer can be cured 
effectively and the relapse of the disease can be avoided.   
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